Cadila Healthcare finalizes definitive agreement with Microbix

24 Aug 2012 Evaluate

Cadila Healthcare has finalized definitive agreement with Microbix regarding re-launch of Urokinase, a critical care therapy in North America. The company, earlier on January 6, 2012, had reached the agreement with Microbix to market Urokinase.

Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

1087.65 11.20 (1.04%)
23-May-2024 15:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1494.95
Dr. Reddys Lab 5882.45
Cipla 1487.45
Zydus Lifesciences 1087.65
Lupin 1631.60
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.